FIGURE 2.
Kaplan–Meier curves for progression‐free survival in atezolizumab plus bevacizumab‐treated patients stratified by mALBI Grade. There was a statistically significant difference between the mALBI 1+2a group and the mALBI 2b+3 group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.